

Association of Free Radicals and the Tissue Renin-Angiotensin System: Prospective Effects of *Rhodiola*, a Genus of Chinese Herb, on Hypoxia-Induced Pancreatic Injury

Siu-Po Ip¹, Chun-Tao Che¹, Po-Sing Leung²

¹School of Chinese Medicine, ²Department of Physiology, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong

Summary

The renin-angiotensin system has long been recognized as crucial factor in the regulation of the systemic blood pressure and renal electrolyte homeostasis. Numerous studies have demonstrated the presence of a local renin-angiotensin system in a variety of organs. A recent study of the pancreatic renin-angiotensin system showed that chronic hypoxia significantly increased the mRNA expression for angiotensinogen II receptor subtypes AT_{1b} and AT₂. The activation of the renin-angiotensin system may play an important role in cellular pathophysiological processes. Angiotensin II enhances the formation of reactive oxygen species via the activation of xanthine oxidase or NAD(P)H oxidase. The reactive oxygen species can cause oxidative damage in the pancreas and other tissues either directly or indirectly via the formation of other radicals such as reactive nitrogen species. *Rhodiola* therapy may protect hypoxia-induced pancreatic injury in two ways. It prevents hypoxia-induced biological changes by increasing intracellular oxygen diffusion and efficiency of oxygen utilization. Alternatively, it reduces hypoxia-induced oxidative damage by its antioxidant activities. Additional experimental data are required to fully elucidate the mode of action of this herbal drug.

Introduction

The renin-angiotensin system (RAS) has long been recognized as crucial in the regulation of the systemic blood pressure and renal electrolyte homeostasis. In 1898, Tigersted and Bergmann discovered renin in rabbit kidney extract which, when injected into rabbits, increased blood pressure [1]. Over the last decade, several components of the RAS have been discovered in a variety of tissues [2]. Under conditions of salt, volume loss, or sympathetic activation, the protease renin is released by the kidney and cleaves liver-derived angiotensinogen to form angiotensin I in the circulating blood. Consequently, angiotensin I is converted into angiotensin II mainly by angiotensin-converting enzyme (ACE). Angiotensin II is the main effector octapeptide which increases blood pressure directly via vascular receptors and indirectly through facilitation of the vasoconstrictor action of the sympathetic nervous system [2].

At least two major angiotensin II receptors, namely AT₁ (AT_{1a} and AT_{1b} subtypes) and AT₂, have been described. The AT₁ subtype mediates the physiological functions of angiotensin II, including hypertrophy, vasoconstriction, and the release of catecholamines from sympathetic nerve endings [3]. The AT₂ subtype is coupled to a phosphotyrosine phosphatase, and is the

dominant receptor expressed in the uterus, adrenal medulla and heart [3, 4, 5].

Based on the discrepancies between RAS blocker-induced changes in the circulating levels of the RAS components and the ability of these receptor blockers to lower the blood pressure, the local RAS was proposed in addition to the circulating RAS. The presence of renin substrate, renin-like enzymatic activity and ACE has been demonstrated in various tissues by means of immunohistochemical and biochemical techniques [3]. Subsequent studies have demonstrated the presence of a local RAS in a variety of organs such as the heart, kidney, adrenal gland, brain, pancreas, and in blood vessels [6, 7, 8, 9, 10, 11].

The expression of major RAS genes can be activated by a number of factors such as hormones and different kinds of stress [12]. Hypoxia is one kind of stress that has been shown to upregulate local RAS components. Recently, a detailed study of pancreatic RAS showed that chronic hypoxia significantly increased the mRNA expression for angiotensinogen, AT_{1b} and AT₂ receptors [13]. It has been reported that the production of free radicals can be increased by hypoxia in the liver [14]. However, it is still unclear whether such a phenomenon can be observed in the pancreas. The possibility that hypoxia may induce oxidative damage in the pancreas and its relationship to the activation of pancreatic RAS will be discussed. In addition, the prospective effects of *Rhodiola*, a genus of Chinese herb, on hypoxia-induced pancreatic injury will be evaluated.

Antioxidant Network

To counteract the potential hazard caused by free radicals, an intricate antioxidant system consisting of both enzymes and small molecules has developed during the course of evolution. Several biological mechanisms against free radicals toxicity have been reported, including highly specific electron transfer pathways, radical scavengers, detoxification enzymes and repair systems [15,


16]. For the non-enzymatic antioxidant system, many free radical scavengers, such as glutathione (GSH), uric acid, beta-carotenes (vitamin A), ascorbic acid (vitamin C) and tocopherols (vitamin E), have been found in cellular systems. These scavengers react directly with free radicals to produce more stable and less toxic products [17].

The enzymatic antioxidant system includes a class of detoxification enzymes. Superoxide dismutases catalyze the dismutation of superoxide anion to hydrogen peroxide. Catalase reduces hydrogen peroxide to water and oxygen and thus prevents the formation of the more reactive hydroxyl radical [18, 19]. Selenium-glutathione peroxidase catalyzes the decomposition of hydrogen peroxide and organic hydroperoxides with the consumption of GSH. Glutathione S-transferases are a family of enzymes that catalyze the reduction of lipid hydroperoxides and the conjugation of electrophilic xenobiotics with GSH to produce less toxic and more water-soluble derivatives for excretion. These reactions result in the accumulation of glutathione disulfide (GSSG) which can crosslink cellular macromolecules and thus impair enzyme-mediated reactions. Nevertheless, GSSG can be reduced intracellularly to GSH by glutathione reductase at the expense of NADPH generated from the pentose phosphate pathway [16, 20].


GSH plays a central role in these reactions. GSH can react directly with hydroxyl radicals and reactive nitrogen species formed from the reaction of superoxide radical and nitric oxide (NO). It regenerates vitamin C and vitamin E from their oxidized forms [21]. It also acts as a substrate for the detoxification of hydrogen peroxide and lipid peroxide catalyzed by glutathione peroxidase and glutathione-S-transferase [16, 20]. Apart from the regeneration from GSSG, the consumed GSH can be replenished by intracellular synthesis (Reactions 1 and 2) from its constituent amino acids which are catalyzed by gamma-

glutamylcysteine synthetase and glutathione synthetase, respectively [22].

Reaction 1:



Reaction 2:



Effects of Hypoxia on Oxidants and Antioxidants

It is reasonable to expect that reactive oxygen species (ROS) production will be reduced under low oxygen tension. However, experimental data have shown that various disturbances resulting from hypoxic stress led to lipid peroxidation and cellular damage [23]. Under hypoxic conditions, cellular components become more reduced and may produce ROS by donating electrons either directly or indirectly to oxygen molecules, also known as reductive stress [24]. In addition, chronic hypoxia may impair endogenous antioxidant defense and render the cells more susceptible to subsequent oxidative injury induced by xenobiotics [25].

The rate of GSH synthesis and the level of GSH have been reported to be affected by the various extent of hypoxia. The level of hepatic GSH was decreased by 25% in rats exposed to 7% oxygen [14] and the rate of GSH synthesis was reduced when rats were exposed to 10.5% oxygen for 10 days [26]. Since the synthesis of each GSH molecule requires two molecules of ATP (Reactions 1 and 2), the decrease of GSH synthesis may be due to the limited supply of ATP during hypoxic conditions. For rats exposed to 10.5% oxygen, the cellular GSH level was unchanged although the maximal GSH synthesis was decreased [26]. It may suggest that the level of GSH is highly dependent on the extent of hypoxia. Under mild hypoxic conditions, the synthesized GSH may be able to maintain its regulated level of GSH. However, when GSH is required for the detoxification processes, the GSH level will be


decreased drastically. It is evidenced by the observation that cells were more susceptible to oxidative injury under hypoxic condition [26]. The phenomenon may result from a combination of deteriorated factors including the decrease of GSH synthesis, the accumulation of GSSG, and the impaired GSH-dependent detoxification reactions in the hypoxic condition where the supplies of ATP and NADPH are inadequate.

It has been reported that the activity of antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase decreases during hypoxia [27]. However, other studies showed that hepatic superoxide dismutase activity was unchanged in rats exposed to 10.5% oxygen for 10 days [26] and increased by 65% in rats during moderate intermittent hypoxia [14]. The discrepancy in these results may suggest that the activity of antioxidant enzymes is highly dependent on the experimental conditions and the duration of hypoxia. Acute hypoxia may cause oxidative damage while mild and chronic hypoxia may induce an adaptive response.


Hypoxia-induced oxidative damage in vascular tissues has been reported in many studies. Hypoxia increased leukocyte sequestration in isolated hearts [28] and adherence of leukocytes to cultured endothelial cells and incubated umbilical vein cells [29, 30]. The increased endothelial adhesive reaction of the leukocytes during hypoxia has been suggested to be mediated by the decrease of the NO level. Experimental results have shown that the production of NO was decreased in endothelial cells during hypoxic conditions *in vitro* and in isolated organs [31, 32]. NO is released from the endothelial cells and plays an important role in the regulation of vascular functions. It acts as an anti-inflammatory mediator which prevents the adhesion of leukocytes to vascular endothelial cells [33, 34, 35]. The decrease of the NO level during hypoxia may be mediated by the reduction of NO synthesis and the increase of NO degradation. Since the oxygen molecule is a substrate in the NO synthesis, it is no doubt that the synthesis is reduced during

hypoxia. Besides, superoxide anion radicals produced during hypoxia can also cause a decrease of the NO level in vascular cells [36]. The superoxide radical reacts with the NO to form peroxynitrite (Reaction 3). Peroxynitrite can isomerize to nitrate (Reaction 4), which is relatively inert to cellular molecules [37]. However, peroxynitrite itself can form a strong oxidant that causes cellular damage by reaction with other biomolecules [38]. Peroxynitrite also reacts with the remaining NO to form nitrogen dioxide (Reaction 5). Nitrogen dioxide reacts with NO to form the nitrosating agent N₂O₃ (Reaction 6) [39]. These reactions further deplete the level of NO and thus enhance the adhesion of leukocytes to the vascular endothelial cells.


Reaction 3:




Reaction 4:



Reaction 5:



Reaction 6:



The involvement of free radicals in hypoxia-induced leukocyte-endothelial adhesive interactions was supported by the observation that an intravenous infusion of antioxidants prevented the formation of ROS and the adhesion of leukocytes in rat mesenteric venules during systemic hypoxia [40].

The Tissue Renin-Angiotensin System as an Initiator of Free Radicals

The activation of pancreatic RAS by chronic hypoxia may be a novel mechanism for the initiation of ROS during hypoxic conditions. In particular, angiotensin II may play a central role in initiating free radical production in local

tissue via different mechanisms, including the activation of xanthine oxidase (XO) and NAD(P)H oxidase.

Like other vasoconstrictors, a transient increase of local angiotensin II may theoretically lead to classic hypoxia-reoxygenation injury that involves XO-mediated free radicals production [41, 42]. Xanthine oxidoreductase exists in two forms, xanthine dehydrogenase (XDH) and XO. The enzymes catalyze two consecutive reactions, the conversions of hypoxanthine to xanthine and xanthine to uric acid. XDH transfers electrons to the oxidized form of nicotinamide adenine dinucleotide (NAD) while XO transfers electrons to molecular oxygen [43, 44]. Both enzymes generate hydrogen peroxide and superoxide radicals when xanthine and oxygen molecules are used as substrates. However, the production of superoxide radicals by XDH is almost completely inhibited by its electron acceptor, NAD. Therefore, the superoxide radical formed in such a way does not cause significant damage in cells that contain sufficient amounts of NAD [44, 45]. But, the superoxide radical produced from XO will initiate oxidative damage. In normal cells, XDH is the predominant form of xanthine oxidoreductase. However, XDH can be converted to XO either by proteolytic cleavage or the oxidation of sulfhydryl residues which occurs rapidly during [46]. In addition, the depletion of ATP and the accumulation of hypoxanthine by hypoxia enhance the generation of ROS during reoxygenation [42].

Apart from the XO pathway, NAD(P)H oxidase has been suggested as an alternative mechanism of free radical formation initiated by angiotensin II [24]. The membrane-bound-NAD(P)H oxidase complex is a FAD-containing flavoprotein which transfers electrons from NAD(P)H to molecular oxygen. The role of angiotensin II in the formation of superoxide radicals by NAD(P)H oxidase has been demonstrated in endothelial cells, vascular smooth muscle cells and mesangial cells [47, 48, 49]. Although the mechanism for the formation of the superoxide radical by

angiotensin II is not fully understood, it is believed that specific binding of angiotensin II to the AT₁ receptor subtype is a possible initiating process [50]. The binding of angiotensin II to the AT₁ receptor stimulates G-protein-coupled phospholipase C and hydrolyzes membrane phosphatidylinositol-4,5-bisphosphate to 1,4,5-inositoltriphosphate and diacylglycerol [51]. The water soluble 1,4,5-inositoltriphosphate stimulates the release of the calcium ion sequestered in the endoplasmic reticulum which, in turn, activates protein kinase C and mitogen-activated protein kinase [52, 53]. Both calcium ions and protein kinase C have been demonstrated to activate NAD(P)H oxidase and elevate superoxide formation [48, 54, 55]. Experimental results from studies of animal and human blood vessels have supported the role of the AT₁ receptor in superoxide production via the activation of membrane-bound NAD(P)H oxidase [48, 56, 57]. The superoxide formed in the vascular cells was blocked by losartan (AT₁ receptor antagonist) and inhibited by diphenylethylidone (inhibitor of NAD(P)H oxidase), respectively [56].

The superoxide produced in this way has been suggested to play an important role in the pathophysiological activity of angiotensin II. The superoxide induced by angiotensin II has been shown to alter vasomotor tone [16], induce hypertrophy in renal tubular cells [58] and vascular smooth muscle cells [59], reduce NO-mediated vasorelaxation [60], stimulate atherosclerosis [57], and enhance endothelial cell apoptosis [61, 62]. The apoptotic effect of angiotensin II has been suggested to be mediated by both AT₁ and AT₂ receptors [61]. In contrast to the signal transduction cascade of the AT₁ receptor, the signaling induced by the specific binding of angiotensin II to the AT₂ receptor has not been well established. Apart from the induction of apoptosis, the function of the AT₂ receptor has been implicated in the inhibition of cell proliferation [63, 64, 65], cell differentiation [66, 67] and neuronal regeneration [68]. In addition, the AT₂ receptor has been shown to stimulate the expression of

adhesion molecules and increase the adhesion of leukocytes to vascular endothelial cells as is done by the superoxide radicals [53].

ACE catalyzes the conversion of angiotensin I to angiotensin II and the degradation of bradykinin [69]. When angiotensin I was added to cultured human endothelial cells, superoxide formation was reduced by the ACE inhibitor and angiotensin receptor antagonists [24]. The effect of the ACE inhibitor was reversed competitively by the addition of angiotensin II further supporting the role of angiotensin II in stimulation of superoxide formation in local tissues [24].

Since chronic hypoxia significantly activates pancreatic RAS including the increased level of angiotensinogen and the upregulation of the AT_{1b} and the AT₂ receptors, it is possible that chronic hypoxia will increase superoxide radical formation in the pancreas and such radical production may be mediated by the stimulating effect of angiotensin II on the activity of XO and NAD(P)H oxidase.

A Simple Principle of Traditional Chinese Medicine

The human body is considered as a whole in traditional Chinese medicine. The objective of Chinese medicine is to maintain a dynamic balance between the two opposing forces, the Yin and the Yang [70]. Health and disease are considered as a harmony and imbalance of these forces, respectively. Superimposed upon the Yin/Yang theory is the concept of Five Elements. The Five Elements are Metal, Wood, Water, Fire, and Earth that can respectively represent the five "solid" organs (Zang), lung, spleen, kidney, heart, and liver in traditional Chinese medicinal theories. The relationship among the Elements is governed by the law of nature such as water can put out fire. For example, for the symptom of high blood pressure, the therapeutic approach is to treat the kidney (Water) in order to control the heart (Fire). It is somehow consistent with the Western medicine as diuretics acts on kidney

rather than heart to increase urination for the purpose of lowering the blood pressure.

The principle of treatment in traditional Chinese medicine is to harmonize the equilibrium of Yin and Yang by regulating body constituents (Qi, Blood, Essence, and Fluids) among the five-organ network. Weak organs are tonified, excess is dispersed, and congested channels are cleared. In the concept of five “solid” organs, the pancreas is associated with the spleen which has the responsibility of “logistics” (digestive function). A disease arising from the weakness of the pancreas (Earth) can be prevented by strengthening the heart (Fire) or dispersing the kidney (Water), in addition to tonifying the organ itself, because Fire engenders Earth and Water restrains Earth in nature.

Effects of *Rhodiola* on Hypoxia-Induced Pancreatic Injury

Rhodiola is a genus of Chinese herb which originates from alpine plants. Over 70 species of *Rhodiola* have been reported to exist in China [71]. *Rhodiola* has been used as a tonic, hemostatic, and for contusions in traditional Chinese medicine for thousands of years. In recent years, its adaptogenic properties [72, 73], anti-hypoxia [74] and anti-fatigue effects [75] and enhancement in learning and memory [76, 77] have been reported.

In traditional Tibetan medicine, *Rhodiola* is commonly used for promoting blood circulation and relieving cough [78]. A recent study has shown that oral administration of *Rhodiola rosea* extract at a dose of 3.5 mg/kg in rats prevented ischemia-reperfusion injury in isolated hearts [79]. This treatment also prevented the decrease of the contraction amplitude and the reduction of coronary blood flow during the postischemia period. The protective effect of *Rhodiola* has been suggested to be associated with the increase of endogenous opioid peptides [79]. A study involving electron microscopic observation showed that oral administration of *Rhodiola kirilowii* prevented high altitude hypoxia-

mediated damage in rat viscera by improving blood circulation [80]. A similar study showed that the anti-hypoxic effect of *Rhodiola semenovii* was associated with a transient lowering of the arterial pressure, a decrease of the heart rate and a lengthening of the cardiac contraction phase [74]. The anti-hypoxia effect of *Rhodiola* has also been attributed to the increase of the oxygen supply and the decrease of oxygen consumption in the respiring cells and the improved efficiency of mitochondrial respiration in skeletal muscle [81].

The *in vitro* and *in vivo* antioxidant activities of *Rhodiola* have been reported in many studies. A recent study of 19 compounds isolated from *Rhodiola sacra* showed that some of the compounds possessed strong scavenger activity against hydroxyl radicals and superoxide anion radicals [82]. *In vivo* studies have shown that treating animals with *Rhodiola* prevented free radical-mediated damage and lipid peroxidation by increasing the concentration of GSH and the activity of superoxide dismutase [81]. A human study showed that treating high altitude polycythemia patients with *Rhodiola* increased superoxide dismutase activity in red blood cells and decreased plasma contents of malondialdehyde [83].

Chronic hypoxia has been shown to induce several biological changes in the pancreas. These changes may be beneficial to the cellular systems such as preparing the cells to adapt to the new environment. However some changes may be harmful such as the potentiation of free radical formation. *Rhodiola* treatment may prevent hypoxia-induced pancreatic injury in two ways. By increasing the availability of intracellular oxygen and the efficiency of oxygen utilization, it reduces the shortage of the oxygen supply and thus minimizes the changes induced by chronic hypoxia. Alternatively, by its scavenger activity and enhancement of endogenous antioxidant defense, it may reduce oxidative injury induced by chronic hypoxia. However, additional experimental data are required to fully elucidate the mode of action of this drug.

Conclusion

Chronic hypoxia causes an activation of pancreatic RAS including the increased expression of angiotensinogen, AT_{1b} and AT₂ receptors. Consequently, ROS may be produced via the activation of XO or NAD(P)H oxidase. The ROS may cause oxidative damage in the pancreas and other tissues either directly or indirectly via the formation of other radicals such as reactive nitrogen species. *Rhodiola* treatment may protect hypoxia-induced pancreatic injury in two ways. It prevents hypoxia-induced biological changes by increasing intracellular oxygen diffusion and the efficiency of oxygen utilization. Alternatively, it reduces hypoxia-induced oxidative damage by its antioxidant activities. The biological mechanisms involved require further elucidation.

Key words Antioxidants; Medicine, Chinese Traditional; Medicine, Herbal; Oxidants; Pancreas; Pancreatic Diseases; Reactive Oxygen Species; Receptors, Angiotensin

Abbreviations ACE: angiotensin-converting enzyme; GSH: glutathione; GSSG: glutathione disulfide; NO: nitric oxide; RAS: renin-angiotensin system; ROS: reactive oxygen species; XDH: xanthine dehydrogenase; XO: xanthine oxidase

Correspondence

Chun-Tao Che
School of Chinese Medicine
The Chinese University of Hong Kong
Shatin, Hong Kong
China
Phone: +852-2609.8130
Fax: +852-2603.7203
E-mail address: cchest@cuhk.edu.hk

References

1. Tigerstedt R, Bergmann P. Niere und Kreislauf. Scand Arch Physiol 1898; 8:223-71.
2. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999; 33(Suppl. 1):S21-8. [99151408]
3. Davis GK, Roberts DH. Molecular genetics of the renin-angiotensin system: implications for angiotensin II receptor blockade. Pharmacol Ther 1997; 75:43-50.
4. Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P, Neuss M, Rolfs A, et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 1995; 91:1461-71.
5. Regitz-Zagrosek V, Neuss M, Warnecke C, Holzmeister J, Hildebrandt AG, Fleck E. Subtype 2 and atypical angiotensin receptors in the human heart. Basic Res Cardiol 1996; 91(Suppl. 2):73-7.
6. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79:1-6.
7. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988; 77:14-13. [88223736]
8. Unger T, Gohlke P, Paul M, Rettig R. Tissue renin-angiotensin systems: fact or fiction?. J Cardiovasc Pharmacol 1991; 18(Suppl. 2):S20-5.
9. Danser AH. Local renin-angiotensin systems. Mol Cell Biochem 1996; 157:211-6.
10. Chappell MC, Diz DI, Jacobsen DW. Pharmacological characterization of angiotensin II binding sites in the canine pancreas. Peptides 1992; 13:313-8. [93027675]
11. Leung PS, Chan WP, Wong TP, Sernia C. Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 1999; 160:13-9. [99077887]
12. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993; 43:1-20. [93150166]
13. Chan WP, Fung ML, Nobiling R, Leung PS. Activation of local renin-angiotensin system by chronic hypoxia in rat pancreas. Mol Cell Endocrinol 2000; 160:107-14. [20181765]
14. Costa LE, Llesuy S, Boveris A. Active oxygen species in the liver of rats submitted to chronic hypobaric hypoxia. Am J Physiol 1993; 264:C1395-400.
15. Coulter CV, Kelso GF, Lin TK, Smith RA, Murphy MP. Mitochondrially targeted antioxidants and thiol reagents. Free Radic Biol Med 2000; 28:1547-54.

16. Shan XQ, Aw TY, Jones DP. Glutathione-dependent protection against oxidative injury. *Pharmacol Ther* 1990; 47:61-71.
17. Giugliano D. Dietary antioxidants for cardiovascular prevention. *Nutr Metab Cardiovas* 2000; 10:38-44.
18. Mates JM, Perez-Gomez C, Nunez de CI. Antioxidant enzymes and human diseases. *Clin Biochem* 1999; 32:595-603.
19. Mates JM, Sanchez-Jimenez F. Antioxidant enzymes and their implications in pathophysiologic processes. *Front Biosci* 1999; 4:D339-45.
20. Sies H. Glutathione and its role in cellular functions. *Free Radic Biol Med* 1999; 27:916-21. [20034912]
21. Chan AC. Partners in defense, vitamin E and vitamin C. *Can J Physiol Pharmacol* 1993; 71:725-31.
22. Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. *Free Radic Biol Med* 1999; 27:922-35.
23. Yoshikawa T, Furukawa Y, Wakamatsu Y, Takemura S, Tanaka H, Kondo M. Experimental hypoxia and lipid peroxide in rats. *Biochem Med* 1982; 27:207-13.
24. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Muge A, Daniel WG. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. *Cardiovasc Res* 1999; 44:215-22. [20082267]
25. El Bassiouni EA, Abo-Ollo MM, Helmy MH, Ismail S, Ramadan MI. Changes in the defense against free radicals in the liver and plasma of the dog during hypoxia and/or halothane anaesthesia. *Toxicology* 1998; 128:25-34.
26. Shan X, Aw TY, Smith ER, Ingelman-Sundberg M, Mannervik B, Iyanagi T, Jones DP. Effect of chronic hypoxia on detoxication enzymes in rat liver. *Biochem Pharmacol* 1992; 43:2421-6. [92304369]
27. Costa LE. Hepatic cytochrome P-450 in rats submitted to chronic hypobaric hypoxia. *Am J Physiol* 1990; 259:C654-9.
28. Gillespie MN, Kojima S, Owasoyo JO, Tai HH, Jay M. Hypoxia provokes leukotriene-dependent neutrophil sequestration in perfused rabbit hearts. *J Pharmacol Exp Ther* 1987; 241:812-6.
29. Arnould T, Michiels C, Remacle J. Increased PMN adherence on endothelial cells after hypoxia: involvement of PAF, CD18/CD11b, and ICAM-1. *Am J Physiol* 1993; 264:C1102-10.
30. Bougelet C, Roland IH, Ninane N, Arnould T, Remacle J, Michiels C. Effect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endothelium. *Eur J Pharmacol* 1998; 345:89-95.
31. Kantrow SP, Huang YC, Whorton AR, Grayck EN, Knight JM, Millington DS, Piantadosi CA. Hypoxia inhibits nitric oxide synthesis in isolated rabbit lung. *Am J Physiol* 1997; 272:L1167-73.
32. Whorton AR, Simonds DB, Piantadosi CA. Regulation of nitric oxide synthesis by oxygen in vascular endothelial cells. *Am J Physiol* 1997; 272:L1161-6.
33. Granger DN. Cell adhesion and migration. II. Leukocyte-endothelial cell adhesion in the digestive system. *Am J Physiol* 1997; 273:G982-6. [98042106]
34. Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. *Cardiovasc Res* 1996; 32:743-51.
35. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. *Gastroenterology* 1998; 114:1066-90.
36. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA* 1990; 87:1620-4. [90160378]
37. Kelm M, Dahmann R, Wink D, Feelisch M. The nitric oxide/superoxide assay. Insights into the biological chemistry of the NO/O₂ interaction. *J Biol Chem* 1997; 272:9922-32. [97248545]
38. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. *Am J Physiol* 1995; 268:L699-722.
39. Miles AM, Bohle DS, Glassbrenner PA, Hansert B, Wink DA, Grisham MB. Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. *J Biol Chem* 1996; 271:40-7. [96132880]
40. Wood JG, Johnson JS, Mattioli LF, Gonzalez NC. Systemic hypoxia promotes leukocyte-endothelial adherence via reactive oxidant generation. *J Appl Physiol* 1999; 87:1734-40.
41. Zhong Z, Arteel GE, Connor HD, Yin M, Frankenberg MV, Stachlewitz RF, et al. Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. *Am J Physiol* 1998; 275:F595-604. [98431937]
42. Saugstad OD. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. *Pediatrics* 1996; 98:103-7.
43. Saito T, Nishino T. Differences in redox and kinetic properties between NAD-dependent and Q-dependent

types of rat liver xanthine dehydrogenase. *J Biol Chem* 1989; 264:10015-22.

44. Nishino T, Nishino T, Schopfer LM, Massey V. The reactivity of chicken liver xanthine dehydrogenase with molecular oxygen. *J Biol Chem* 1989; 264:2518-27.

45. Nishino T. The conversion of xanthine dehydrogenase to xanthine oxidase and the role of the enzyme in reperfusion injury. *J Biochem (Tokyo)* 1994; 116:1-6. [95096003]

46. Waud WR, Rajagopalan KV. The mechanism of conversion of rat liver xanthine dehydrogenase from an NAD⁺-dependent form (type D) to an O₂-dependent form (type O). *Arch Biochem Biophys* 1976; 172:365-79.

47. Radeke HH, Cross AR, Hancock JT, Jones OT, Nakamura M, Kaefer V, Resch K. Functional expression of NADPH oxidase components (alpha- and beta-subunits of cytochrome b558 and 45-kDa flavoprotein) by intrinsic human glomerular mesangial cells. *J Biol Chem* 1991; 266:21025-9.

48. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ Res* 1994; 74:1141-8.

49. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. *J Clin Invest* 1993; 91:2546-51.

50. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. *Kidney Int* 1998; 54:775-84.

51. Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MA Jr., Alexander RW. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. *J Biol Chem* 1986; 261:5901-6.

52. Brock TA, Rittenhouse SE, Powers CW, Ekstein LS, Gimbrone MA Jr., Alexander RW. Phorbol ester and 1-oleoyl-2-acetyl-glycerol inhibit angiotensin activation of phospholipase C in cultured vascular smooth muscle cells. *J Biol Chem* 1985; 260:14158-62.

53. Regitz-Zagrosek V, Neuss M, Holzmeister J, Warnecke C, Fleck E. Molecular biology of angiotensin receptors and their role in human cardiovascular disease. *J Mol Med* 1996; 74:233-51.

54. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG. Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. *Arterioscler Thromb* 1994; 14:1007-13.

55. Agwu DE, McPhail LC, Sozzani S, Bass DA, McCall CE. Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on

activation of NADPH oxidase. *J Clin Invest* 1991; 88:531-9.

56. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. *Circulation* 2000; 101:2206-12. [20263651]

57. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. *Circulation* 1999; 99:2027-33. [99225407]

58. Hannken T, Schroeder R, Stahl RA, Wolf G. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. *Kidney Int* 1998; 54:1923-33.

59. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, et al. Role of NADH/NADPH oxidase-derived H₂O₂ in angiotensin II-induced vascular hypertrophy. *Hypertension* 1998; 32:488-95. [98413202]

60. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. *Circ Res* 2000; 86:E85-90. [20270563]

61. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. *Circ Res* 1997; 81:970-6.

62. Walter DH, Haendeler J, Galle J, Zeiher AM, Dimmeler S. Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. *Circulation* 1998; 98:1153-7.

63. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT₂-receptor mediates inhibition of cell proliferation in coronary endothelial cells. *J Clin Invest* 1995; 95:651-7.

64. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, et al. The angiotensin II type 2 (AT₂) receptor antagonizes the growth effects of the AT₁ receptor: gain-of-function study using gene transfer. *Proc Natl Acad Sci USA* 1995; 92:10663-7. [96068676]

65. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. *Hypertension* 1996; 27:760-5.

66. Laflamme L, Gasparo M, Gallo JM, Payet MD, Gallo-Payet N. Angiotensin II induction of neurite outgrowth by AT₂ receptors in NG108-15 cells. Effect

counteracted by the AT₁ receptors. J Biol Chem 1996; 271:22729-35. [96394341]

67. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT₂ receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996; 122:59-67.

68. Gallinat S, Csikos T, Meffert S, Herdegen T, Stoll M, Unger T. The angiotensin AT₂ receptor down-regulates neurofilament M in PC12W cells. Neurosci Lett. 1997; 227:29-32. [97322197]

69. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991; 68:905-21.

70. Wiseman N, Ellis A. Fundamentals of Chinese medicine. Massachusetts: Paradigm Publications, 1996.

71. Ming HQ, Xia GC, Zheng RZ. Advanced research on *Rhodiola*. Chinese Herb Med 1988; 19:229-34.

72. Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin VV. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of *Rhodiola rosea* SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine 2000; 7:85-9.

73. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phytother Res 1999; 13:275-91.

74. Kurmukov AG, Aizikov MI, Rakhimov SS. Pharmacology of the plant polyphenol epigalokhin. Farmakol Toksikol 1986; 49:45-8.

75. Azizov AP, Seifulla RD. The effect of elton, leveton, fitoton and adapton on the work capacity of experimental animals. Eksp Klin Farmakol 1998; 61:61-3.

76. Tezuka Y, Fan W, Kasimu R, Kadota S. Screening of crude drug extracts for prolyl endopeptidase inhibitory activity. Phytomedicine 1999; 6:197-203.

77. Fan W, Tezuka Y, Komatsu K, Namba T, Kadota S. Prolyl endopeptidase inhibitors from the underground part of *Rhodiola sacra* S. H. Fu. Biol Pharm Bull 1999; 22:157-61.

78. Peng JN, Ge YC, Li XH. Studies on the chemical constituents of *Rhodiola fastigita*. Acta Pharmaceut Sin 1996; 31:798-800.

79. Lishmanov I, Naumova AV, Afanas'ev SA, Maslov LN. Contribution of the opioid system to realization of inotropic effects of *Rhodiola rosea* extracts in ischemic and reperfusion heart damage *in vitro*. Eksp Klin Farmakol 1997; 60:34-6.

80. Zhang Z, Wang L, Chen Q, Feng S, Cao Z, Zhou X, et al, Electron microscopic observation of the effects of *Rhodiola kirilowii* (Regel.) Maxim. in preventing

damage of the rat viscera by a hypoxic high altitude environment. China Journals of Chinese Materia Medica 1990; 15:177-81.

81. Hongjingtian. In Zheng HZ, Dong ZH, She J, eds. Modern Study of Traditional Chinese Medicine. Volume 6. 1st ed. Beijing: Beijing Xue Yuan Press, 1997: 5658-78.

82. Ohsugi M, Fan W, Hase K, Xiong Q, Tezuka Y, Komatsu K, et al. Active-oxygen scavenging activity of traditional nourishing-tonic herbal medicines and active constituents of *Rhodiola sacra*. J Ethnopharmacol 1999; 67:111-9.

83. Xi AQ, Zhang XS, Lu XM. Effect of Sanpu Hongjingtian (*Rhodiola* sp) capsule on erythrocyte deformability and oxygen free radical in patients with high altitude polycythemia. Chinese Traditional and Herbal Drugs 2000; 442-4.